Complications of biological therapy for inflammatory bowel diseases
Authors:
- Gary R LichtensteinGLGary R Lichtenstein
- 1 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 22 (1) , 30-43
Abstract
The purpose of this review is to analyze the complications associated with treatment of inflammatory bowel disease with biologic agents. There have been various biologic agents evaluated in patients with inflammatory bowel disease; that is, Crohn's disease and ulcerative colitis. Thus far only infliximab has been approved by the US Food and Drug Administration as induction and maintenance treatment in patients with active Crohn's disease (moderate-to-severe and/or fistulizing) who are refractory to conventional therapy. Recent data from two large multicenter, multicountry, randomized controlled clinical trials have demonstrated that infliximab is efficacious also for the treatment of ulcerative colitis. Other biologics considered potentially efficacious are still undergoing evaluation in various clinical trials. The data concerning biologics' associated toxicity in patients with inflammatory bowel disease are the most robust in the case of infliximab. These data are derived from both prospective, randomized clinical trials and from post-marketing experience. In the case of the remaining agents the data concerning safety in inflammatory bowel disease are limited, as these agents were not evaluated in as many trials as infliximab; indeed, some of them included only several patients.Keywords
This publication has 76 references indexed in Scilit:
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Natalizumab and Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2005
- Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisAmerican Journal of Gastroenterology, 2004
- A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitisGut, 2003
- Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Prospective evaluation of interferon-α in treatment of chronic active Crohn's diseaseDigestive Diseases and Sciences, 1995